BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. The company reported sales of $747 ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.

Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you ...

BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO ...

Parents Hailey and Juan Lucero said they knew what to expect having their daughter, Adaliyah as a preemie, but what they did ...

The mother at the centre of Melanie Reid’s latest podcast investigation is set to be deported in the coming weeks, despite ...

Before a ball is even kicked, Eoin Doyle is relishing the prospect of a four-way battle for the Premier Division title.

CHARGE syndrome in two; trisomy 21; Noonan syndrome; and infantile spinal muscular atrophy), two in group 3 (Rubinstein Taybi syndrome; Ivemark syndrome) and two in group 4 (trisomy 21 ...

These tumors are not cancer. Noonan syndrome. This condition affects many parts of the body. Children with Noonan syndrome may be short and have wide-set eyes, heart defects, and bleeding problems.

Suzhou Genhouse Bio Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, Noonan syndrome and ...